aztreonam has been researched along with Leukemia in 9 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fourty-two febrile episodes of 32 patients with hematologic disease during neutropenia were treated with two randomly assigned antibiotic combinations of either piperacillin plus gentamicin or piperacillin plus aztreonam." | 9.07 | [Aztreonam or gentamicin combined with piperacillin as empiric antibiotic therapy during neutropenia of patients with hematologic diseases]. ( Murase, T, 1992) |
| "A combination of aztreonam (AZT) and clindamycin (CLDM) was evaluated for severe infections associated with leukemia and related disorders." | 7.67 | [Clinical evaluation of a combination therapy with aztreonam and clindamycin for severe infections in leukemia and related disorders]. ( Abe, T; Horiike, S; Inazawa, J; Misawa, S; Nakagawa, H; Nishigaki, H; Okuda, T; Tanaka, S; Taniwaki, M; Tsuda, S, 1989) |
| "Fourty-two febrile episodes of 32 patients with hematologic disease during neutropenia were treated with two randomly assigned antibiotic combinations of either piperacillin plus gentamicin or piperacillin plus aztreonam." | 5.07 | [Aztreonam or gentamicin combined with piperacillin as empiric antibiotic therapy during neutropenia of patients with hematologic diseases]. ( Murase, T, 1992) |
| " Thus, both the adverse prognostic effect of leukemia as an underlying disease and the poorer results obtained using aztreonam-containing regimens were evident only with certain outcome definitions." | 5.06 | The effect of different measures of outcome on the results of studies of empiric antibiotic therapy in febrile neutropenic patients. ( Elliott, CR; Pater, JL, 1988) |
| "A combination of aztreonam (AZT) and clindamycin (CLDM) was evaluated for severe infections associated with leukemia and related disorders." | 3.67 | [Clinical evaluation of a combination therapy with aztreonam and clindamycin for severe infections in leukemia and related disorders]. ( Abe, T; Horiike, S; Inazawa, J; Misawa, S; Nakagawa, H; Nishigaki, H; Okuda, T; Tanaka, S; Taniwaki, M; Tsuda, S, 1989) |
| "Nineteen patients with hematological malignancies (5 malignant lymphomas, 9 acute leukemia and 5 other hematological diseases) were treated with aztreonam alone or in combination for infection." | 3.67 | Treatment of infections during hematologic malignancies with aztreonam, a new antibiotic. ( Invernizzi, R; Mazzone, A; Nastasi, G; Ricevuti, G; Rizzo, SC, 1986) |
| "One hundred and nine patients with infection accompanying hematologic disorders including leukemia and lymphoma were treated with aztreonam (AZT)." | 3.67 | [Therapeutic effectiveness of aztreonam on severe infections associated with hematologic disorders. Hanshin Infection Study Group]. ( Hirayama, F; Horiuchi, A; Kawagoe, H; Kitani, T; Masaoka, T; Nagai, K; Okamoto, Y; Shibata, H; Yasunaga, K; Yonezawa, T, 1985) |
| "There was one infection-related death among patients assigned to AAT therapy and also one among those assigned to LAT therapy." | 2.66 | [Empiric therapy with aztreonam for febrile neutropenic patients with hematological malignancies]. ( Ichimaru, M; Moriuchi, Y; Soda, H; Tomonaga, M; Toriya, K, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Toyama, K | 1 |
| Yaguchi, M | 1 |
| Mizoguchi, H | 1 |
| Masuda, M | 1 |
| Urabe, A | 1 |
| Ikeda, Y | 1 |
| Aoki, I | 1 |
| Shinbo, T | 1 |
| Togawa, A | 1 |
| Hirashima, K | 1 |
| Miura, Y | 1 |
| Hirose, S | 1 |
| Tsuruoka, N | 1 |
| Omine, M | 1 |
| Kamakura, M | 1 |
| Saito, T | 1 |
| Arimori, S | 1 |
| Aoki, N | 1 |
| Kuraishi, Y | 1 |
| Hirai, H | 1 |
| Asano, S | 1 |
| Mori, M | 1 |
| Shirai, T | 1 |
| Muto, Y | 1 |
| Takaku, F | 1 |
| Murase, T | 1 |
| Bodey, G | 1 |
| Reuben, A | 1 |
| Elting, L | 1 |
| Kantarjian, H | 1 |
| Keating, M | 1 |
| Hagemeister, F | 1 |
| Koller, C | 1 |
| Velasquez, W | 1 |
| Papadopoulos, N | 1 |
| Spencer, RC | 1 |
| Taylor, AK | 1 |
| Winfield, DA | 1 |
| Moriuchi, Y | 1 |
| Soda, H | 1 |
| Toriya, K | 1 |
| Tomonaga, M | 1 |
| Ichimaru, M | 1 |
| Tsuda, S | 1 |
| Tanaka, S | 1 |
| Nakagawa, H | 1 |
| Nishigaki, H | 1 |
| Okuda, T | 1 |
| Horiike, S | 1 |
| Taniwaki, M | 1 |
| Misawa, S | 1 |
| Inazawa, J | 1 |
| Abe, T | 1 |
| Elliott, CR | 1 |
| Pater, JL | 1 |
| Rizzo, SC | 1 |
| Ricevuti, G | 1 |
| Invernizzi, R | 1 |
| Mazzone, A | 1 |
| Nastasi, G | 1 |
| Hirayama, F | 1 |
| Masaoka, T | 1 |
| Shibata, H | 1 |
| Nagai, K | 1 |
| Kitani, T | 1 |
| Horiuchi, A | 1 |
| Kawagoe, H | 1 |
| Yasunaga, K | 1 |
| Okamoto, Y | 1 |
| Yonezawa, T | 1 |
6 trials available for aztreonam and Leukemia
| Article | Year |
|---|---|
Effect of recombinant human granulocyte colony-stimulating factor on combination therapy with aztreonam and clindamycin for infections in neutropenic patients with hematologic diseases.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aztreonam; Clindamycin; Drug Therapy, Com | 1996 |
[Aztreonam or gentamicin combined with piperacillin as empiric antibiotic therapy during neutropenia of patients with hematologic diseases].
Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Aztreonam; Bacterial Infections; Cefamandole; Drug Therap | 1992 |
Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever.
Topics: Aztreonam; Bacterial Infections; Cefoperazone; Drug Administration Schedule; Drug Therapy, Combinati | 1991 |
A comparative efficacy and safety study of teicoplanin plus aztreonam versus gentamicin plus piperacillin in haematology oncology patients with clinically diagnosed septicaemia.
Topics: Adult; Anti-Bacterial Agents; Aztreonam; Bacteria; Drug Therapy, Combination; Female; Gentamicins; G | 1990 |
[Empiric therapy with aztreonam for febrile neutropenic patients with hematological malignancies].
Topics: Aztreonam; Drug Evaluation; Drug Therapy, Combination; Fever; Humans; Infections; Leukemia; Lymphoma | 1989 |
The effect of different measures of outcome on the results of studies of empiric antibiotic therapy in febrile neutropenic patients.
Topics: Acute Disease; Agranulocytosis; Anti-Bacterial Agents; Aztreonam; Clinical Trials as Topic; Cloxacil | 1988 |
3 other studies available for aztreonam and Leukemia
| Article | Year |
|---|---|
[Clinical evaluation of a combination therapy with aztreonam and clindamycin for severe infections in leukemia and related disorders].
Topics: Adult; Aged; Aged, 80 and over; Aztreonam; Bacterial Infections; Clindamycin; Drug Evaluation; Drug | 1989 |
Treatment of infections during hematologic malignancies with aztreonam, a new antibiotic.
Topics: Acute Disease; Aztreonam; Bacterial Infections; Humans; Leukemia; Lymphoma | 1986 |
[Therapeutic effectiveness of aztreonam on severe infections associated with hematologic disorders. Hanshin Infection Study Group].
Topics: Adolescent; Adult; Aged; Aztreonam; Bacterial Infections; Drug Evaluation; Drug Resistance, Microbia | 1985 |